-+ 0.00%
-+ 0.00%
-+ 0.00%

Benchmark Downgrades Humacyte to Speculative Buy, Lowers Price Target to $1

Benzinga·03/31/2026 15:18:53
Listen to the news
Benchmark analyst Bruce D. Jackson downgrades Humacyte (NASDAQ:HUMA) from Buy to Speculative Buy and lowers the price target from $10 to $1.